Thyroid Fine-Needle Aspiration (FNA) Guidelines
Introduction to Thyroid FNA Categories
- The National Comprehensive Cancer Network recommends classifying thyroid FNA results into six standardized diagnostic categories that guide clinical management based on malignancy risk, with Category II having a risk of malignancy of ≤5% and management involving clinical follow-up with ultrasound surveillance at 12-18 months initially, then 3-5 year intervals if stable 1
Management of Thyroid FNA Categories
- The National Comprehensive Cancer Network suggests that Category IV: Follicular Neoplasm or Suspicious for Follicular Neoplasm, which includes Hürthle cell neoplasms, has a risk of malignancy of 15-40% and management involves surgical lobectomy for definitive diagnosis 2
- Molecular diagnostic testing may be useful for evaluating indeterminate FNA samples (Categories III and IV), and if molecular testing suggests benign lesion (risk ≤5%), active surveillance may be appropriate, according to the National Comprehensive Cancer Network 2
- The National Comprehensive Cancer Network recommends that if molecular testing suggests malignancy, surgical intervention is recommended 2
Special Considerations
- The Annals of Oncology notes that Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is a reclassification of certain encapsulated non-invasive follicular PTC variants with excellent prognosis 3
- The National Comprehensive Cancer Network advises against relying solely on nodule size for management decisions and considers ultrasound features and clinical context, as false-negative results can occur 4
- The Annals of Oncology recommends avoiding overdiagnosis and overtreatment of small, subclinical papillary thyroid carcinomas 3
- Certain entities (follicular carcinomas, NIFTP) cannot be definitively diagnosed by FNA alone, according to the Annals of Oncology 3